CVR number 20554398
Industry 32.5000 Manufacture of medical and dental instruments and supplies

H.C. DAHLS EFTF. ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  2.2% 2.2% 2.2% 2.2% 2.2%  
Bankruptcy risk  6.7% 5.5% 3.9% 10.4% 8.2%  
Credit score (0-100)  36 40 50 22 30  
Credit rating  BBB BBB BBB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  1,383 1,493 1,336 922 1,234  
EBITDA  412 588 410 -14.7 289  
EBIT  412 586 404 -21.1 283  
Pre-tax profit (PTP)  435.0 615.7 433.5 -2.2 301.3  
Net earnings  334.6 477.6 337.4 -1.6 237.0  
Pre-tax profit without non-rec. items  435 616 433 -2.2 301  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  0.0 29.3 23.0 16.7 10.4  
Shareholders equity total  468 584 470 131 368  
Interest-bearing liabilities  0.0 107 156 143 83.7  
Balance sheet total (assets)  1,241 1,167 952 468 734  
Net Debt  -190 101 150 137 77.4  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,383 1,493 1,336 922 1,234  
Gross profit growth  9.1% 8.0% -10.5% -31.0% 33.8%  
Employees  2 2 2 2 2  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,241 1,167 952 468 734  
Balance sheet change%  53.4% -6.0% -18.4% -50.9% 56.8%  
Added value  412.3 588.3 410.1 -14.7 289.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 27 -13 -13 -13  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  5.0 5.0 5.0 -1.0 1.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  29.8% 39.2% 30.2% -2.3% 22.9%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  43.1% 52.0% 41.9% 0.8% 51.5%  
ROI %  92.9% 99.7% 67.2% 1.2% 85.1%  
ROE %  86.6% 90.8% 64.0% -0.5% 94.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  37.7% 50.0% 49.4% 28.1% 50.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -46.0% 17.2% 36.6% -928.8% 26.8%  
Gearing %  0.0% 18.4% 33.2% 108.7% 22.7%  
Net interest  0 0 0 0 0  
Financing costs %  27.1% 19.7% 7.8% 5.1% 7.3%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.8 1.9 1.9 1.3 2.0  
Current Ratio  1.8 2.0 1.9 1.3 2.0  
Cash and cash equivalent  189.7 6.5 6.1 5.9 6.3  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  563.5 555.6 448.6 115.4 358.7  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  206 294 205 -7 145  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  206 294 205 -7 145  
EBIT / employee  206 293 202 -11 141  
Net earnings / employee  167 239 169 -1 118